Catalent has formed an advisory board to shape growth of the company’s biologics business.
Founding members of the advisory board are: Carolyn Bertozzi, Barry Buckland, Michael Buckley, Daniel Marshak and Edward Robinson. They have diverse expertise in biologics development and commercialisation, new technologies, contract services and a deep understanding of the key challenges facing biologics developers.
Bertozzi is the Anne and Robert Bass Professor of Chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. She co-founded Redwood Bioscience, which was acquired by Catalent in 2014, and is currently Chair of Redwood’s Scientific Advisory Board.
Buckland spent approximately 30 years at Merck & Co, most recently as Vice President and head of the Bioprocess R&D organisation at Merck Research Laboratories.
Buckley has more than 30 years of experience in the biotech industry, most recently in the position of Vice President of Core Technology and Vice President of Process Sciences at Takeda Pharmaceuticals. He previously held executive positions with Neugenesis, Genitope and Corixa.
Marshak is currently Director on the Board of InVivo Therapeutics, a medical device and biotechnology company in Cambridge, MA. He was most recently Senior Vice President and Chief Scientific Officer for Perkin Elmer and previously Vice President and Chief Technology Officer, Biotechnology, for Cambrex and Senior Vice President and Chief Scientific Officer of Osiris Therapeutics where he led stem cell research from inception to late stage clinical trials.
Robinson is currently Chairman & CEO of Acadia Harvest and also has more than 30 years of experience in the biotech industry. He was previously served an Executive Vice President at Cambrex, President of Solutia Pharmaceutical Services, and President of Lonza Biologics.
The new advisory board will complement the existing Redwood Bioscience Scientific Advisory Board, consisting of key thought leaders in biologics development and protein chemistry.
